Loss of normal kidney function affects more than 10% of the population and contributes to
morbidity and mortality. Kidney diseases are currently treated with immunosuppressive …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic
potential. Dose is predicted at many stages in drug discovery and development. Prior to the …

The rise of novel artificial intelligence (AI) methods necessitates their benchmarking against
classical machine learning for a typical drug-discovery project. Inhibition of the potassium …

Breast cancer (BC), the most common malignancy in women, results from significant
alterations in genetic and epigenetic mechanisms that alter multiple signaling pathways in …

Background: Current standard of care (SOC) regimens against nontuberculous
mycobacteria (NTM) usually result in unsatisfactory therapeutic responses, primarily due to …

Alkaloids found in multiple species, known as 'driver species', are more likely to be included
in early-stage drug development due to their high biodiversity compared to rare alkaloids …

Cryptosporidiosis is caused by infection of the small intestine by Cryptosporidium parasites,
resulting in severe diarrhea, dehydration, malabsorption, and potentially death. The only …

BACKGROUND: STREAM (Standardized Treatment Regimen of Anti-TB Drugs for Patients
with MDR-TB) Stage 1 demonstrated non-inferior efficacy of a shortened regimen (the Short …

Drug-induced gastrointestinal toxicity (GIT) is a common treatment-emergent adverse event
that can negatively impact dosing, thereby limiting efficacy and treatment options for …